Bank Of America Corp Pro Qr Therapeutics N.V. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Bank Of America Corp holds 73,163 shares of PRQR stock, worth $133,156. This represents 0.0% of its overall portfolio holdings.

Number of Shares

73,163

Previous 110,107 33.55%

Holding current value

$133,156

Previous $252,000 51.98%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.65 - $2.39 $60,957 - $88,296	-36,944 Reduced 33.55%	73,163 $121,000
Q1 2024 May 15, 2024	BUY	$1.89 - $2.85 $60,204 - $90,783	31,854 Added 40.71%	110,107 $252,000
Q4 2023 Feb 14, 2024	SELL	$1.15 - $2.21 $87,667 - $168,474	-76,233 Reduced 49.35%	78,253 $154,000
Q2 2023 Aug 14, 2023	BUY	$1.62 - $2.32 $2,519 - $3,607	1,555 Added 1.02%	154,486 $250,000
Q1 2023 May 12, 2023	BUY	$1.99 - $3.66 $239,926 - $441,271	120,566 Added 372.52%	152,931 $325,000
Q4 2022 Feb 10, 2023	BUY	$0.8 - $3.7 $9 - $44	12 Added 0.04%	32,365 $119,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $0.89 $1,593 - $1,917	-2,154 Reduced 6.24%	32,353 $24,000
Q2 2022 Aug 12, 2022	BUY	$0.56 - $1.0 $8,369 - $14,946	14,946 Added 76.41%	34,507 $26,000
Q1 2022 May 16, 2022	SELL	$0.9 - $8.39 $151,501 - $1.41 Million	-168,335 Reduced 89.59%	19,561 $18,000
Q4 2021 Feb 08, 2022	BUY	$6.58 - $8.44 $747,211 - $958,429	113,558 Added 152.76%	187,896 $1.51 Million
Q3 2021 Nov 15, 2021	BUY	$5.16 - $8.47 $375,235 - $615,938	72,720 Added 4494.44%	74,338 $622,000
Q2 2021 Sep 13, 2021	BUY	$5.75 - $7.59 $9,303 - $12,280	1,618 New	1,618 $11,000

Others Institutions Holding PRQR

# of Institutions

Shares Held

17.2M

Call Options Held

26.2K

Put Options Held

8.6K

View Full List

About ProQR Therapeutics N.V.

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $130M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

More about PRQR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Pro Qr Therapeutics N.V. Transaction History